| scholarly article | Q13442814 |
| P50 | author | Emilie Henin | Q43094730 |
| Gilles Freyer | Q79780278 | ||
| P2093 | author name string | Olivia Le Saux | |
| Amina Mohtaram | |||
| Naoual Bakrin | |||
| Claire Falandry | |||
| Salima Hamizi | |||
| P2860 | cites work | Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab | Q27640593 |
| Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 | ||
| Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group | Q27824835 | ||
| Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 | ||
| Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene | Q27860693 | ||
| Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets | Q28140238 | ||
| Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells | Q28201813 | ||
| Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial | Q28254919 | ||
| Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer | Q29547699 | ||
| Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer | Q29616112 | ||
| Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). | Q33730975 | ||
| Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. | Q33964848 | ||
| The six hyaluronidase-like genes in the human and mouse genomes | Q34103842 | ||
| Adjuvant trastuzumab in HER2-positive breast cancer | Q35710898 | ||
| Home-based subcutaneous immunoglobulin G replacement therapy under real-life conditions in children and adults with antibody deficiency. | Q35959163 | ||
| Hyaluronan | Q36001372 | ||
| Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration | Q36903813 | ||
| Subcutaneous immunoglobulin: opportunities and outlook | Q37626132 | ||
| Review of the mechanism of action and clinical efficacy of recombinant human hyaluronidase coadministration with current prandial insulin formulations | Q37716042 | ||
| Hyaluronidase: a review of approved formulations, indications and off-label use in chronic pain management | Q37737317 | ||
| Adjuvants to local anaesthesia in ophthalmic surgery | Q37858272 | ||
| Safety and pharmacokinetics of subcutaneous ceftriaxone administered with or without recombinant human hyaluronidase (rHuPH20) versus intravenous ceftriaxone administration in adult volunteers | Q43233644 | ||
| The INFUSE-Morphine IIB study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneous morphine in healthy volunteers | Q43263909 | ||
| The INFUSE-Morphine study: use of recombinant human hyaluronidase (rHuPH20) to enhance the absorption of subcutaneously administered morphine in patients with advanced illness | Q43263911 | ||
| Angioedema related to the use of hyaluronidase in cataract surgery | Q44963914 | ||
| Hyaluronidase and its substrate hyaluronan: biochemistry, biological activities and therapeutic uses | Q45345655 | ||
| Comparison of subcutaneous and intravenous administration of trastuzumab: a phase I/Ib trial in healthy male volunteers and patients with HER2-positive breast cancer | Q46087752 | ||
| Factors influencing route of administration for epoetin treatment among hemodialysis patients in the United States. | Q51939149 | ||
| Prognostic factors for health-related quality of life in adults and children with primary antibody deficiencies receiving SCIG home therapy. | Q53171720 | ||
| Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I–III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial | Q57579927 | ||
| Flow-assisted diagnosis of anaphylaxis to hyaluronidase | Q58617680 | ||
| A recombinant human enzyme for enhanced interstitial transport of therapeutics | Q64377594 | ||
| The serum kinetics of bovine testicular hyaluronidase in dogs, rats and humans | Q70406091 | ||
| Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer | Q79794472 | ||
| Effect of hyaluronidase on the subcutaneous absorption of electrolytes in humans | Q80645601 | ||
| Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial | Q81353003 | ||
| Recombinant human hyaluronidase-enabled subcutaneous pediatric rehydration | Q84634340 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | trastuzumab | Q412616 |
| P304 | page(s) | 89-94 | |
| P577 | publication date | 2013-02-14 | |
| P1433 | published in | OncoTargets and Therapy | Q7092081 |
| P1476 | title | Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer | |
| P478 | volume | 6 |
| Q89547608 | Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer |
| Q58583000 | Development of New Formulations of Biologics: Expectations, Immunogenicity, and Safety for Subcutaneous Trastuzumab |
| Q38654371 | Fixed Dosing of Monoclonal Antibodies in Oncology |
| Q53354258 | Measuring tissue back-pressure--in vivo injection forces during subcutaneous injection. |
| Q92255092 | Overcoming Drug Resistance by Taking Advantage of Physical Principles: Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) |
| Q38198973 | Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer |
| Q91910615 | The comparative efficacy and risk of harms of the intravenous and subcutaneous formulations of trastuzumab in patients with HER2-positive breast cancer: a rapid review |
Search more.